Highlights BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
4.45 ^USD	-0.67%		+6.97%	-25.71%

Apr. 17	BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	MT
Apr. 17	BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17	CI
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	Feb. 26	MT
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M	Feb. 26	MT
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 26	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
BioCryst Launches Hereditary Angioedema Drug in Italy	Feb. 20	MT
BioCryst Launches Orladeyo (Berotralstat) in Italy	Feb. 19	CI
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit	Jan. 05	MT
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Jan. 05	CI
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)	Dec. 19	CI
BioCryst Pharmaceuticals Receives Argentine Regulatory Approval for Orladeyo	Nov. 29	MT
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina	Nov. 29	CI
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO	Nov. 21	CI
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)	Nov. 10	CI
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration	Nov. 03	MT
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q3 Revenue $86.7M, vs. Street Est of $86.1M	Nov. 02	MT
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023	Nov. 02	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology	23-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Highlights

Filters